Estren is a selective estrogen receptor modulator with transcriptional activity.

It was recently reported that the synthetic compound estren increases bone mass without affecting reproductive organs or classic transcription. The aim of the present study was to further characterize the in vivo and in vitro effects of estren. We demonstrate that estren is a selective estrogen receptor modulator (SERM) with a strong effect on thymus, a moderate effect on uterus and trabecular bone, but no major effect on fat or cortical bone in 11-month-old ovariectomized mice. The effect of estren on trabecular bone and uterus is mediated via estrogen receptors (ERs) because no effect is seen in ER double-inactivated mice. Furthermore, with the use of ERalpha- and ERbeta-expressing reporter cell lines, we demonstrate that estren displays an agonistic effect on transcriptional activity of an estrogen-responsive element-driven reporter gene with a degree of agonism similar to that of 17beta-estradiol for both ERalpha and ERbeta. Thus, estren has the capacity to exert genomic effects via both ERalpha and ERbeta. We conclude, in contrast to what was previously reported by others, that estren is a SERM with transcriptional activity.

[1]  J. Gustafsson,et al.  Differential effects on bone of estrogen receptor α and androgen receptor activation in orchidectomized adult male mice , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[2]  L. Hartmann,et al.  Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice. , 2003, The New England journal of medicine.

[3]  A. Parfitt,et al.  Reversal of bone loss in mice by nongenotropic signaling of sex steroids. , 2003, Science.

[4]  S. Mohan,et al.  Two Different Pathways for the Maintenance of Trabecular Bone in Adult Male Mice , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[5]  R. Jilka,et al.  Sex steroids and bone. , 2002, Recent progress in hormone research.

[6]  S. Safe,et al.  Estrogen Receptor-mediated Activation of the Serum Response Element in MCF-7 Cells through MAPK-dependent Phosphorylation of Elk-1* , 2001, The Journal of Biological Chemistry.

[7]  B. Katzenellenbogen,et al.  Nongenotropic, Sex-Nonspecific Signaling through the Estrogen or Androgen Receptors Dissociation from Transcriptional Activity , 2001, Cell.

[8]  J. Compston,et al.  Sex steroids and bone. , 2001, Physiological reviews.

[9]  R. Métivier,et al.  Function of N-terminal transactivation domain of the estrogen receptor requires a potential alpha-helical structure and is negatively regulated by the A domain. , 2000, Molecular endocrinology.

[10]  A. Bilancio,et al.  Steroid‐induced androgen receptor–oestradiol receptor β–Src complex triggers prostate cancer cell proliferation , 2000, The EMBO journal.

[11]  K. Ley,et al.  Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase , 2000, Nature.

[12]  J. Gustafsson,et al.  Estrogen receptor specificity in the regulation of skeletal growth and maturation in male mice. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[13]  J. Gustafsson,et al.  Increased cortical bone mineral content but unchanged trabecular bone mineral density in female ERbeta(-/-) mice. , 1999, The Journal of clinical investigation.

[14]  B. McEwen,et al.  Estrogen actions in the central nervous system. , 1999, Endocrine reviews.

[15]  J. Gustafsson,et al.  Generation and reproductive phenotypes of mice lacking estrogen receptor beta. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[16]  J. Gustafsson,et al.  Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists. , 1998, Molecular pharmacology.

[17]  J. Gustafsson,et al.  Differential Response of Estrogen Receptor a and Estrogen Receptor b to Partial Estrogen Agonists/Antagonists , 1998 .

[18]  C. Christiansen,et al.  Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. , 1997, The New England journal of medicine.

[19]  S. Kato,et al.  Rapid activation of MAP kinase by estrogen in the bone cell line. , 1997, Biochemical and biophysical research communications.

[20]  M. Wehling.  Specific, nongenomic actions of steroid hormones. , 1997, Annual review of physiology.

[21]  K. Korach,et al.  Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[22]  R. Hochberg,et al.  A simple and sensitive microtiter plate estrogen bioassay based on stimulation of alkaline phosphatase in Ishikawa cells: estrogenic action of delta 5 adrenal steroids. , 1990, Endocrinology.

[23]  P. Chambon,et al.  Role of the two activating domains of the oestrogen receptor in the cell‐type and promoter‐context dependent agonistic activity of the anti‐oestrogen 4‐hydroxytamoxifen. , 1990, The EMBO journal.

[24]  K. Pavelić,et al.  In Vivo Effect of Progesteron and Estrogen on Thymus Mass and T-Cell Functions in Female Mice , 1984, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.